All Stories

  1. MP24-17 INTERLEUKIN-15 DOWNREGULATES INHIBITORY NATURAL KILLER(NK) CELL LIGANDS EXPRESSED ON PROSTATE CANCER CELLS RESULTING IN INCREASED NK CELL ACTIVITY IN PROSTATE CANCER-IMMUNE EFFECTOR CELL COCULTURES.

    Article • The Journal of Urology, April 2014, Elsevier

    Dr Christine Galustian

  2. Mechanism of activation of natural killer and CD8 T cells by interleukin 15 in the prostate cancer microenvironment

    Article • The Lancet, February 2014, Elsevier

    Dr Christine Galustian

  3. Tools to investigate biomarker expression in bladder cancer progression

    Article • BJU International, July 2013, Wiley

    Dr Christine Galustian

  4. Enhanced cross-priming of naive CD8+T cells by dendritic cells treated by the IMiDs®immunomodulatory compounds lenalidomide and pomalidomide

    Article • Immunology, June 2013, Wiley

    Dr Christine Galustian, Professor Prokar Dasgupta

  5. 1335 IL-15 INHIBITS EXPRESSION OF KILLER INHIBITORY NK RECEPTORS AND UPREGULATES EXPRESSION OF NKG2D ON NK AND NKT CELLS IN PROSTATE CANCER-PBMC COCULTURES

    Article • The Journal of Urology, April 2013, Elsevier

    Dr Christine Galustian

  6. Immunologic Aspects of Prostate Cancer

    Article • December 2012, Springer Science + Business Media

    Dr Christine Galustian

  7. 328 PS20 INHIBITS EXPANSION OF CD8-T CELLS AND NK CELLS IN THE PROSTATE CANCER MICROENVIRONMENT AND INHIBITS KILLING OF PROSTATE CANCER CELLS

    Article • The Journal of Urology, April 2012, Elsevier

    Dr Christine Galustian

  8. The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics

    Article • APOPTOSIS, November 2011, Springer Science + Business Media

    Dr Christine Galustian

  9. Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins

    Article • Biochemical Society Transactions, October 2011, Portland Press Ltd.

    Dr Christine Galustian, Professor Prokar Dasgupta

  10. 1789 SELECTION OF OPTIMAL CYTOKINE COMBINATIONS FOR IMMUNOTHERAPY OF PROSTATE CANCER

    Article • The Journal of Urology, April 2011, Elsevier

    Dr Christine Galustian

  11. Pomalidomide

    Article • Drugs of the Future, January 2011, Prous Science

    Dr Christine Galustian

  12. The potential of immunomodulatory drugs in the treatment of solid tumors

    Article • Future Oncology, September 2010, Future Medicine

    Dr Christine Galustian

  13. Recent Pharmacological Advances: Focus on Small-cell Lung Cancer

    Article • Clinical Medicine Insights Therapeutics, July 2010, Libertas Academica, Ltd.

    Dr Christine Galustian

  14. The Power of the Web in Cancer Drug Discovery and Clinical Trial Design: Research without a Laboratory?

    Article • Cancer Informatics, February 2010, Libertas Academica, Ltd.

    Dr Christine Galustian

  15. A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro

    Article • Molecular Biology Reports, July 2009, Springer Science + Business Media

    Dr Christine Galustian

  16. Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer

    Article • Current Clinical Pharmacology, May 2009, Bentham Science Publishers

    Dr Christine Galustian

  17. The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy

    Article • Current Signal Transduction Therapy, May 2009, Bentham Science Publishers

    Dr Christine Galustian

  18. Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors

    Article • The American Journal of Surgery, February 2009, Elsevier

    Dr Christine Galustian

  19. Lenalidomide: a novel anticancer drug with multiple modalities

    Article • Expert Opinion on Pharmacotherapy, December 2008, Informa Healthcare

    Dr Christine Galustian

  20. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

    Article • Cancer Immunology Immunotherapy, November 2008, Springer Science + Business Media

    Dr Christine Galustian

  21. Thalidomide-derived immunomodulatory drugs as therapeutic agents

    Article • Expert Opinion on Biological Therapy, December 2004, Informa Healthcare

    Dr Christine Galustian

  22. The Immunomodulatory Drug (IMID®) CC-4047 Enhances the Proliferation and Anti-Tumor Function of Gamma Delta T Cells

    Article • Journal of Immunotherapy, November 2004, Wolters Kluwer Health

    Dr Christine Galustian

  23. Interactions of the gastrotropic bacterium Helicobacter pylori with the leukocyte–endothelium adhesion molecules, the selectins – a preliminary report

    Article • FEMS Immunology & Medical Microbiology, May 2003, Oxford University Press (OUP)

    Dr Christine Galustian

  24. Neoglycolipid Technology: Deciphering Information Content of Glycome

    Article • January 2003, Elsevier

    Dr Christine Galustian

  25. Synthesis and selectin-binding activity of N-deacetylsialyl Lewis X ganglioside

    Article • Carbohydrate Research, November 2002, Elsevier

    Dr Christine Galustian

  26. Oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions

    Article • Nature Biotechnology, September 2002, Springer Science + Business Media

    Dr Christine Galustian

  27. Synergistic interactions of the two classes of ligand, sialyl-Lewisaxfuco-oligosaccharides and short sulpho-motifs, with the P- and L-selectins: implications for therapeutic inhibitor designs

    Article • Immunology, March 2002, Wiley

    Dr Christine Galustian

  28. Transcription Factor NF??B Expression and Postsurgical Organ Dysfunction

    Article • Annals of Surgery, January 2001, Wolters Kluwer Health

    Dr Christine Galustian

  29. Recombinant Soluble Human CD69 Dimer Produced in Escherichia coli: Reevaluation of Saccharide Binding

    Article • Biochemical and Biophysical Research Communications, December 1999, Elsevier

    Dr Christine Galustian

  30. Novel oligosaccharide ligands and ligand-processing pathways for the selectins

    Article • Trends in Biochemical Sciences, October 1999, Elsevier

    Dr Christine Galustian

  31. Die erste Totalsynthese des 6-Sulfo-de-N-acetylsialyl-Lewisx-Gangliosids: ein hervorragender Ligand für menschliches L-Selectin

    Article • Angewandte Chemie, April 1999, Wiley

    Dr Christine Galustian

  32. Die erste Totalsynthese des 6-Sulfo-de-N-acetylsialyl-Lewisx-Gangliosids: ein hervorragender Ligand für menschliches L-Selectin

    Article • Angewandte Chemie, April 1999, Wiley

    Dr Christine Galustian

  33. The First Total Synthesis of 6-Sulfo-de-N-acetylsialyl Lewisx Ganglioside: A Superior Ligand for Human L-Selectin

    Article • Angewandte Chemie International Edition, April 1999, Wiley

    Dr Christine Galustian

  34. Sialyl-LewisxSequence 6-O-Sulfated atN-Acetylglucosamine Rather Than at Galactose Is the Preferred Ligand forl-Selectin and De-N-acetylation of the Sialic Acid Enhances the Binding Strength

    Article • Biochemical and Biophysical Research Communications, April 1998, Elsevier

    Dr Christine Galustian

  35. Sialyl-LewisxSequence 6-O-Sulfated atN-Acetylglucosamine Rather Than at Galactose Is the Preferred Ligand forl-Selectin and De-N-acetylation of the Sialic Acid Enhances the Binding Strength

    Article • Biochemical and Biophysical Research Communications, November 1997, Elsevier

    Dr Christine Galustian

  36. Valency Dependent Patterns of Binding of Human L-Selectin toward Sialyl and Sulfated Oligosaccharides of Le a and Le x Types:  Relevance to Anti-Adhesion Therapeutics †

    Article • Biochemistry, April 1997, American Chemical Society (ACS)

    Dr Christine Galustian

  37. Actin cytoskeletal isoforms in human endothelial cellsin vitro: Alteration with cell passage

    Article • In Vitro Cellular & Developmental Biology - Animal, November 1995, Springer Science + Business Media

    Dr Christine Galustian

  38. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity

    Article • Immunopharmacology, March 1994, Elsevier

    Dr Christine Galustian